NEK2 and cancer: NEK2A accumulation serves as a prognostic marker for poor patient outcomes, promotes cancer cell proliferation, and is found to be upregulated across a multitude of cancers including prostate, breast, colorectal, cervical, hepatocellular carcinoma, and lung cancer [227].